Effects of adalimumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis
Modern Rheumatology, 07/05/2012
Tsuji S et al. – Adalimumab exerted its effect as early as week 4, and it was sustained until the end of the 24–week observation period in the psoriatic arthritis (PsA) patients.Methods
- Patients who initiated adalimumab therapy after March 2010 were followed for at least 24 weeks with the clinical outcome measures.
- Eleven patients, all men with a mean age of 45.4 years, had mean psoriasis durations of 16.2 and 8.4 years at baseline.
- After 24 weeks, 72.7, 63.6, and 45.5 % of the patients met the ACR 20, 50, and 70 response criteria, respectively, while 81.8 % achieved the PsA response criteria.
- Disease Activity Score using the 28–joint count and CRP declined from 3.2 ± 1.2 at baseline to 1.3 ± 0.4 at week 24 (P < 0.01).
- The Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index scores also decreased significantly (both P values were <0.01).
- After 24 weeks, three out of eight dimensions of the Medical Outcomes Study 36–Item Short Form Health Survey and Physical Component Summary were significantly improved (all P values were <0.05).